anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
lncRNA can regulate tumorigenesis development and distant metastasis of colorectal cancer (CRC). However, the detailed molecular mechanisms are still largely unknown. Using RNA-sequencing data, RT-qPCR, and FISH assay, we found that HIF1A-AS2 was upregulated in CRC tissues and associated with poor prognosis. Functional experiments were performed to determine the roles of HIF1A-AS2 in tumor progression and we found that HIF1A-AS2 can promote the proliferation, metastasis, and aerobic glycolysis of CRC cells. Mechanistically, HIF1A-AS2 can promote FOXC1 expression by sponging miR-141-3p. SP1 can transcriptionally activate HIF1A-AS2. Further, HIF1A-AS2 can be packaged into exosomes and promote the malignant phenotype of recipient tumor cells. Taken together, we discovered that SP1-induced HIF1A-AS2 can promote the metabolic reprogramming and progression of CRC via miR-141-3p/FOXC1 axis. HIF1A-AS2 is a promising diagnostic marker and treatment target in CRC.
1. A pharmaceutical composition comprising a therapeutically effective amount of lymphotoxin-β receptor (LT-β-R) blocking agent and a pharmaceutically acceptable carrier. 2. The composition according to claim 1, wherein the LT-β-R blocking agent is selected from the group consisting of a soluble lymphotoxin-β receptor with an amino sequence SEQ.ID.NO.1, an antibody directed against lymphotoxin-β receptor (LT-β-R), an antibody directed against the surface lympfotoxin lygand (LT lygand). 3. The composition according to claim 2, wherein the soluble lymphotoxin-β receptor is a ligand binding domain having a ligand binding domain that can selectively bind to a surface LT ligand. 4. The composition according to claim 3, wherein the soluble lymphotoxin-β receptor further comprises a human immunoglobulin Fc domain. 5. The composition according to claim 2, wherein the LT-β-R blocking agent is a monoclonal antibody directed against LT-β receptor. 6. The composition according to claim 5, wherein the monoclinal antibody is mAb BDA8 directed against LT-β-R of a human. 7. The composition according to claim 2, wherein the LT-β-R blocking agent is a monoclonal antibody directed against LT-β receptor. 8. The composition according to claim 7, wherein, the antibody is directed against a subunit of the LT ligand. 9. The composition according to claim 7, wherein the monoclonal antibody is mAb B9 directed against LT-β of a human. 10. The composition according to claim 7, wherein the LT-β-R blocking agent is a monoclonal antibody directed against the LT ligand of a mouse. 11. A method for treating or reducing the advancement, severity or effects of an immunological disease in a mammal by inhibiting LT-β receptor signalling, wherein comprising administering to the mammal a pharmaceutical composition according to any claim 1 to 10. 12. The method for inhibiting the Th1 cell-mediated immune response signalling, wherein comprising administering to the mammal a pharmaceutical composition according to any claim 1 to 10. 13. The method according to claim 12, wherein the Th1 cell-mediated immune response contributes to cellular rejection of tissue in the mammal after the mammal receives a tissue graft. 14. The method according to claim 12, wherein the Th1 cell-mediated immune response contributes to organ rejection in the mammal after the mammal receives an organ transplant. 15. The method according to claim 15, wherein the Th1 cell-mediated immune response contributes to an autoimmune disorder in the mammal. 16. The method according to claim 15, wherein the autoimmune disorder is selected from the group consisting of multiple sclerosis, insulin-dependent diabetes, sympathetic ophthalmia, uveitis and psoriasis. 17. The method according to claim 12, wherein the Th1 cell-mediated immune response is inhibited without inhibiting a Th2 cell-dependent immune response. 18. The method for treating inflammatory bowel disease in a mammal, wherein comprising administering to the mammal a pharmaceutical composition according to claim 4.
Acid sphingomyelinase (ASM) inhibitors are widely used for the treatment of post-stroke depression. They promote neurological recovery in animal stroke models via neurorestorative effects. In a previous study, we found that antidepressants including amitriptyline, fluoxetine, and desipramine increase cerebral angiogenesis post-ischemia/reperfusion (I/R) in an ASM-dependent way. To elucidate the underlying mechanisms, we investigated the effects of the functional ASM inhibitor amitriptyline in two models of I/R injury, that is, in human cerebral microvascular endothelial hCMEC/D3 cells exposed to oxygen-glucose deprivation and in mice exposed to middle cerebral artery occlusion (MCAO). In addition to our earlier studies, we now show that amitriptyline increased mitochondrial reactive oxygen species (ROS) formation in hCMEC/D3 cells and increased ROS formation in the vascular compartment of MCAO mice. ROS formation was instrumental for amitriptyline's angiogenic effects. ROS formation did not result in excessive endothelial injury. Instead, amitriptyline induced a profound metabolic reprogramming of endothelial cells that comprised reduced endothelial proliferation, reduced mitochondrial energy metabolism, reduced endoplasmic reticulum stress, increased autophagy/mitophagy, stimulation of antioxidant responses and inhibition of apoptotic cell death. Specifically, the antioxidant heme oxygenase-1, which was upregulated by amitriptyline, mediated amitriptyline's angiogenic effects. Thus, heme oxygenase-1 knockdown severely compromised angiogenesis and abolished amitriptyline's angiogenic responses. Our data demonstrate that ASM inhibition reregulates a complex network of metabolic and mitochondrial responses post-I/R that contribute to cerebral angiogenesis without compromising endothelial survival.
Pediatric emergencies are rare events that require precise medical intervention. The dosing of medication is particularly tricky. The challenges require technical aids for automatic dosage calculation without restricting the emergency physicians' ability to act. This short paper describes the development process of an automatic data processing pipeline that synchronizes multiple sensor data to perform the necessary calculations. In a final evaluation process, two transmission protocols (HTTP and MQTT)), are compared to determine which is more suitable for this application. The results of the evaluation clearly showed that MQTT is the preferred choice for the data processing pipeline due to its significantly lower latency.
Patients receive the daily reminder message via app (Emento) that they should pay attention to sufficient calorie intake. In addition, these patients receive 3 screening questions about their current health and nutritional status twice a week.
Patients receive a fitness tracker, a booklet "Physical training, exercise and cancer" and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients physical activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy.
Flucytosine Capsules, USP are an antifungal agent available as 250 mg and 500 mg capsules for oral administration. In addition to the active ingredient of flucytosine, each capsule contains corn starch, lactose monohydrate and talc. The 250 mg capsule shell contains FD&C Yellow No. 6, FD&C Green No. 3, D&C Yellow No. 10, titanium dioxide, sodium lauryl sulfate and gelatin. The 500 mg capsule shell contains iron oxide yellow, iron oxide black, titanium dioxide, carboxymethylcellulose, sodium lauryl sulfate and gelatin. The imprinting ink used for 250 mg and 500 mg capsules contains black iron oxide.

Chemically, flucytosine is 5-fluorocytosine, a fluorinated pyrimidine which is related to fluorouracil and floxuridine. It is a white to off-white crystalline powder with a molecular weight of 129.09 and the following structural formula:
AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing circulating insulin levels.

Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas, the biguanides, or the alpha-glucosidase inhibitors.

Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, (Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base). The molecule has a single chiral center and is present as a racemate. Due to rapid interconversion, the enantiomers are functionally indistinguishable. The structural formula of rosiglitazone maleate is:

The molecular formula is C18H19N3O3S•C4H4O4. Rosiglitazone maleate is a white to off-white solid with a melting point range of 122° to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1. It is readily soluble in ethanol and a buffered aqueous solution with pH of 2.3; solubility decreases with increasing pH in the physiological range.

Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide, triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides and talc.
Nontuberculous mycobacteria (NTM) are widespread environmental organisms found in both natural and man-made settings, such as building plumbing, water distribution networks and hospital water systems. Their ubiquitous presence increases the risk of transmission, leading to a wide range of human infections, particularly in immunocompromised individuals. NTM primarily spreads through environmental exposures, such as inhaling aerosolized particles, ingesting contaminated food and introducing it into wounds. Hospital-associated outbreaks have been linked to contaminated medical devices and water systems. Furthermore, the rising global incidence, prevalence and isolation rates highlight the urgency of addressing NTM infections. Gaining a thorough insight into the sources and epidemiology of NTM infection is crucial for devising novel strategies to prevent and manage NTM transmission and infections.
A method comprises extracting the crushed ground parts of the plant cheese-bowel yellow Glaucium Flavum Crantz by 1% solution of hydrochloric acid, leaching and extracting by ethyl acetate. The ethyl acetate extract is purified by 3% solution of potassium alkali. After treatment by sulphuric acid and alkali basic alkaloids are transferred to chloroform. The chloroform extracts are evaporated in the vacuum to receive the solid residue. The obtained basic glaucium is transferred to hydrochloride, for which it is dissolved in hot methanol and concentrated hydrochloric acid is added thereto. The obtained glaucium hydrochloride is purified by light petroleum and acetone. The yield of glaucium hydrochloride makes 0,23%.
PURPOSE: Previous studies have shown increased prevalence of sleep problems among people who stutter. However, there is a lack of knowledge about what these sleep problems may specifically be.
METHOD: Fifty children who stutter (CWS) from 6;0 to 12;9 years of age and 50 age- and gender-matched controls participated in this study. Parents did not report coexisting conditions, excepting stuttering and/or sleep problems. Sleep problems were investigated using a standardized questionnaire answered by parents. The questionnaire shows cut-off scores to identify the risk of sleep problems as a whole and on each one of the six subscales (i.e., disorders of initiating and maintaining sleep; sleep breathing disorders; disorders of arousal; sleep-wake transition disorders; disorders of excessive somnolence; and sleep hyperhidrosis). Scores above the cut-off are suggestive of sleep problems.
RESULTS: Twenty-one CWS scored higher than the cut-off on the sleep questionnaire compared to only two controls (p < 0.00001). Specifically, CWS scored higher than controls in disorders of initiating and maintaining sleep, sleep-wake transition disorders (especially jerking, sleep talking, and bruxism), and disorders of excessive somnolence (p < 0.0083, corrected for multiple comparisons).
DISCUSSION: Compared to controls, CWS are at greater risk for sleep problems, which are not consequences of coexisting disorders. Present findings confirm and expand current knowledge about sleep problems in CWS. Directionality possibilities and clinical implications are discussed.
A process for the preparation of a respiration-stimulating active substance comprises subjecting the blood of slaughter-animals to dialysis to effect substantially complete deproteination and to effect complete removal of protein particles having a molecular weight in excess of approximately 3000 therefrom and concentrating the dialysate thereby obtained to a dry content of 10-60 mg/ml., preferably at least 30 mg/ml.  The dialysis is preferably effected in a tube of "Cellophane" (Registered Trade Mark) employing as solvents water or dilute alcohol.  Prior to dialysis the blood may be subjected to a preliminary deproteination by fractional precipitation with alcohols, e.g. straight or branched chain aliphatic alcohols containing from 1-6 carbon atoms or acid such as trichloracetic acid or preferably perchloric acid.  The concentrated dialysate may be purified by precipitation with aliphatic ketones or alcohols containing from 1-6 carbon atoms, acetone being a particularly useful precipitant, or by extraction with a water-immiscible or partly immiscible solvent such as aliphatic alcohols with 3-8 carbon atoms, e.g. butanol, or aliphatic ethers with 2-12 carbon atoms and both resulting phases worked up. Preferably the blood is subjected to a pretreatment before dialysis or before the preliminary deproteination preceding dialysis, such as haemolysis, treatment with acetone, spray-drying, defibrination, peptic and/or tryptic digestion. The crude concentrate and/or purified concentrate may be evaporated to dryness, dissolved in distilled water and sterile filtered and freeze-dried under sterile conditions.  Phenol and cresol may be added as preservatives.  The crude concentrate after sterile filtration can be applied directly.  The blood used is preferably that of young slaughter-animals and may come from animals which have been put into a condition of altered activity by mechanical or chemical treatment or by irradiation. Blood-cells and plasma may be separated and worked up separately.
Hemiplegic cerebral palsy in the most common type of cerebral palsy that has permanent motor disorders and associated with life-long disability. the aim of study to assess the efficacy of mirror therapy on balance in children with hemiplegic cerebral palsy. Seventy child with hemiplegic cerebral were enrolled in this study and were assessed for eligibility. Their aged ranged from eight to twelve years. The children were assigned randomly into two equal groups. Group (a) control group received traditional physical therapy program. And group (b) study group received the same traditional physical therapy program in addition to mirror therapy three times / weak for three successful months. Biodex balance system was used to assess balance pre and post treatment. All children were assisted before and after three months of intervention.
Disclosed is a method for modulating wound healing in a mammal. The method includes the steps of: (a) administering a photosensitizer to a mammal that has an unhealed or partially-healed wound; (b) waiting for the photosensitizer to reach an effective tissue concentration at the wound site; (c) photoactivating the photosensitizer by delivering specifically to the wound site light of a effective wavelength and intensity, for an effective length of time. The modulation of wound healing can include hastening healing by administering a low dose of photodynamic therapy. Alternatively, the modulation can include inhibiting fibrosis by administering a high dose of photodynamic therapy. The photosensitizer can be targeted, for example, to macrophages or myofibroblasts. Targeting can be by conjugation to a targeting moiety such as a protein, peptide or microparticle.
The aim of the study is to investigate the effects of a 4-week, unilateral balance exercise training program on bilateral balance and explosive power in athletes with chronic ankle instability (CAI). The study included 28 volunteer athletes with a history of CAI who registered as a team player at Yeditepe University Culture and Sports Directorate February 2019 - June 2019. The severity of functional ankle instability of all the athletes was assessed by the Cumberland Ankle Instability Tool (CAIT). Functional limitations of the athletes with CAI were evaluated by Foot and Ankle Ability Measure Activity of Daily Living Subscale (FAAM-ADL) and Sports Subscale (FAAM-S). Balance Error Scoring System (BESS) was used to determine the static balance performance of athletes. Dynamic balance was evaluated by the Y Balance Test (YBT). Sport performance including vertical jumping and hopping was assessed with Single-Legged Countermovement Jump (CMJ) Test, Figure-of-Eight Hop Test, and Side Hop Test. The athletes were randomly divided into Rehabilitation for the Stable Ankle Group (SG) (n=9), Rehabilitation for the Unstable Ankle Group (UG) (n=9) and Control Group (CG) (n=10). Athletes in SG and UG were included balance exercise training program. The balance exercise training program was administered for only the stable ankle of athletes in SG and only the unstable ankle of athletes in UG, twice a week and for a 4-week duration.
BACKGROUND: The current risk stratification methods for Pediatric Differentiated Thyroid Carcinoma (DTC) are deemed inadequate due to the high recurrence rates observed in this demographic. This study investigates alternative clinicopathological factors, specifically the Central Lymph Node Ratio (CLNR), for improved risk stratification in pediatric DTC.
METHODS: A retrospective review of 100 pediatric DTC patients, aged 19 or younger, treated between December 2012 and January 2021 at the First Affiliated Hospital of Guangxi Medical University was conducted. Clinicopathological variables were extracted, and univariate logistic regression identified factors correlated with recurrence. Kaplan-Meier (KM) survival analysis and subsequent statistical tests were used to assess the significance of these factors.
RESULTS: The CLNR, with a cutoff value of 77.78%, emerged as a significant predictor of recurrence. Patients with a CLNR above this threshold had a 5.467 times higher risk of recurrence. The high CLNR group showed a higher proportion of male patients, clinically lymph node positivity (cN1), and extrathyroidal extension (ETE) compared to the low-risk group (p<0.05).
CONCLUSION: CLNR is a valuable predictor for recurrence in pediatric DTC and aids in stratifying patients based on Recurrence-Free Survival (RFS). For patients with a high CLNR, aggressive iodine-131 therapy, stringent TSH suppression, and proactive postoperative surveillance are recommended to mitigate recurrence risk and facilitate timely detection of recurrent lesions.
<P>PROBLEM TO BE SOLVED: To provide new antiallergic agents and histamine isolation inhibitors, and a safe cosmetic composition containing at least one of them.  <P>SOLUTION: The antiallergic agents contain ε-polylysine. The histamine isolation inhibitors contain ε-polylysine. The safe cosmetic composition contains at least one of them. The ε-polylysine is allowed to use free ε-polylysine; an inorganic salt of ε-polylysine formed by ε-polylysine with such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid; and an organic salt of ε-polylysine formed by ε-polylysine with such organic salts as acetic acid, propionic acid, fumaric acid, malic acid, citric acid, maleic acid, adipic acid, gluconic acid and lactic acid. The cosmetic composition improves eczema, pimples and skin roughness; gives gloss, firmness and moistness to the skin; and is safe for humans and animals.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Glial cells provide physical and chemical support and protection for neurons and for the extracellular compartments of neural tissue through secretion of soluble factors, insoluble scaffolds, and vesicles. Additionally, glial cells have regenerative capacity by remodeling their physical microenvironment and changing physiological properties of diverse cell types in their proximity. Various types of aberrant glial and macrophage cells are associated with human diseases, disorders, and malignancy. We previously demonstrated that transmembrane protein, TMEM230 has tissue revascularization and regenerating capacity by its ability to secrete pro-angiogenic factors and metalloproteinases, inducing endothelial cell sprouting and channel formation. In healthy normal neural tissue, TMEM230 is predominantly expressed in glial and marcophate cells, suggesting a prominent role in neural tissue homeostasis. TMEM230 regulation of the endomembrane system was supported by co-expression with RNASET2 (lysosome, mitochondria, and vesicles) and STEAP family members (Golgi complex). Intracellular trafficking and extracellular secretion of glial cellular components are associated with endocytosis, exocytosis and phagocytosis mediated by motor proteins. Trafficked components include metalloproteins, metalloproteinases, glycans, and glycoconjugate processing and digesting enzymes that function in phagosomes and vesicles to regulate normal neural tissue microenvironment, homeostasis, stress response, and repair following neural tissue injury or degeneration. Aberrantly high sustained levels TMEM230 promotes metalloprotein expression, trafficking and secretion which contribute to tumor associated infiltration and hypervascularization of high tumor grade gliomas. Following injury of the central nervous or peripheral systems, transcient regulated upregulation of TMEM230 promotes tissue wound healing, remodeling and revascularization by activating glial and macrophage generated microchannels/microtubules (referred to as vascular mimicry) and blood vessel sprouting and branching. Our results support that TMEM230 may act as a master regulator of motor protein mediated trafficking and compartmentalization of a large class of metalloproteins in gliomas and gliosis.
All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score \</=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.
The experimental group will receive treatment program designed to train strategic cognitive functions. Sessions will last 50 minutes and take place twice per week for 16 weeks.